Mechanistic study of the effect of Endothelin SNPs in microvascular angina – Protocol of the PRIZE Endothelin Sub-Study

Abraham, G. R., Morrow, A. J. , Oliveira, J., Weir-McCall, J. R., Davenport, E. E., Berry, C. , Davenport, A. P. and Hoole, S. P. (2022) Mechanistic study of the effect of Endothelin SNPs in microvascular angina – Protocol of the PRIZE Endothelin Sub-Study. International Journal of Cardiology: Heart and Vasculature, 39, 100980. (doi: 10.1016/j.ijcha.2022.100980)

[img] Text
267608.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Introduction: Microvascular angina is a common cause of ischemia with non-obstructive coronary arteries (INOCA) and limited therapeutic options are available to those affected. Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in the pathophysiology of microvascular angina. A large randomised, double blinded, placebo controlled crossover trial, the PRecIsion medicine with ZibotEntan in microvascular angina (PRIZE) trial is currently underway, investigating an endothelin receptor antagonist – Zibotentan, as a new drug treatment for microvascular angina. The trial uses a 'precision medicine' approach by preferential selection of those with higher ET-1 expression conferred by the PHACTR1 minor G allele single nucleotide polymorphism (SNP). The incidence of this SNP occurs in approximately one third of the population therefore a considerable number of screened patients will be ineligible for randomisation and the treatment phase of the trial. Methods: In the PRIZE Endothelin (ET) Sub-Study, patients screened out of the PRIZE trial will be genotyped for other genetic variants in the ET-1 pathway. These will be correlated with phenotypic characteristics including exercise tolerance, angina severity and quantitative measures of microvascular function on cardiovascular MRI as well as mechanistic data on endothelin pathway signalling. Conclusions: The study will provide a comprehensive genotype and phenotype bio-resource identifying novel ET-1 genotypes to inform the potential wider use of endothelin receptor antagonists for this indication.

Item Type:Articles
Additional Information:This research was funded in whole, or in part, by the British Heart Foundation [CB, RE/18/6134217], Medical Research Council [CB, MR/S018905/1], Wellcome Trust [EED, 206194; 108413/A/15/D; APD, WT107715/Z/15/Z].
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Morrow, Dr Andrew and Berry, Professor Colin
Authors: Abraham, G. R., Morrow, A. J., Oliveira, J., Weir-McCall, J. R., Davenport, E. E., Berry, C., Davenport, A. P., and Hoole, S. P.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:International Journal of Cardiology: Heart and Vasculature
Publisher:Elsevier
ISSN:2352-9067
Published Online:25 February 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
303684A randomized, double-blind, placebo-controlled Phase 2A cross-over trial of oral zibotentan in patients with angina due to small vessel disease: a proof-of-concept, developmental trial for safety, efficacy and biomarkers developmentColin BerryMedical Research Council (MRC)MR/S018905/1CAMS - Cardiovascular Science